Literature DB >> 34515792

New insights into the low-grade glioma tumor microenvironment for improved patient management.

Miriam Bornhorst1,2,3.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 34515792      PMCID： PMC8730777          DOI： 10.1093/neuonc/noab224

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   13.029


× No keyword cloud information.
  7 in total

1.  Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.

Authors:  Grant W Simmons; Winnie W Pong; Ryan J Emnett; Crystal R White; Scott M Gianino; Fausto J Rodriguez; David H Gutmann
Journal:  J Neuropathol Exp Neurol       Date:  2011-01       Impact factor: 3.685

2.  Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation.

Authors:  Winnie W Pong; Samantha B Higer; Scott M Gianino; Ryan J Emnett; David H Gutmann
Journal:  Ann Neurol       Date:  2013-02-19       Impact factor: 10.422

3.  Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.

Authors:  Nicholas Butowski; Howard Colman; John F De Groot; Antonio M Omuro; Lakshmi Nayak; Patrick Y Wen; Timothy F Cloughesy; Adhirai Marimuthu; Sam Haidar; Arie Perry; Jason Huse; Joanna Phillips; Brian L West; Keith B Nolop; Henry H Hsu; Keith L Ligon; Annette M Molinaro; Michael Prados
Journal:  Neuro Oncol       Date:  2015-10-08       Impact factor: 12.300

4.  Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial.

Authors:  Adam L Cohen; Christopher J Anker; Brett Johnson; Lindsay M Burt; Dennis C Shrieve; Karen Salzman; Randy Jensen; Ken Boucher; Howard Colman
Journal:  J Neurooncol       Date:  2020-06-06       Impact factor: 4.130

5.  RNA sequence analysis reveals ITGAL/CD11A as a stromal regulator of murine low-grade glioma growth.

Authors:  Amanda De Andrade Costa; Jit Chatterjee; Olivia Cobb; Shilpa Sanapala; Suzanne Scheaffer; Xiaofan Guo; Sonika Dahiya; David H Gutmann
Journal:  Neuro Oncol       Date:  2022-01-05       Impact factor: 13.029

6.  RNA Sequencing of Tumor-Associated Microglia Reveals Ccl5 as a Stromal Chemokine Critical for Neurofibromatosis-1 Glioma Growth.

Authors:  Anne C Solga; Winnie W Pong; Keun-Young Kim; Patrick J Cimino; Joseph A Toonen; Jason Walker; Todd Wylie; Vincent Magrini; Malachi Griffith; Obi L Griffith; Amy Ly; Mark H Ellisman; Elaine R Mardis; David H Gutmann
Journal:  Neoplasia       Date:  2015-10       Impact factor: 5.715

7.  Whole tumor RNA-sequencing and deconvolution reveal a clinically-prognostic PTEN/PI3K-regulated glioma transcriptional signature.

Authors:  Yuan Pan; Erin C Bush; Joseph A Toonen; Yu Ma; Anne C Solga; Peter A Sims; David H Gutmann
Journal:  Oncotarget       Date:  2017-04-18
  7 in total
  2 in total

1.  PD-L2 Serves as a Potential Prognostic Biomarker That Correlates With Immune Infiltration and May Predict Therapeutic Sensitivity in Lower-Grade Gliomas.

Authors:  Qijun Xie; Xianlong Huang; Wu Huang; Fang Liu
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

2.  Prognosis of Oligodendroglioma Patients Stratified by Age: A SEER Population-Based Analysis.

Authors:  Kai Jin; Shu-Yuan Zhang; Li-Wen Li; Yang-Fan Zou; Bin Wu; Liang Xia; Cai-Xing Sun
Journal:  Int J Gen Med       Date:  2021-12-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.